Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients

NCT02565134 is registered in ClinicalTrials.gov with Amorepacific Corporation as lead sponsor.

NCT NCT02565134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients
Lead sponsor
Amorepacific Corporation
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
July 31, 2016
Enrollment
296 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin pruritus